This is a complete list of clinically approved prescription
antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or
mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for
major depressive disorder unless noted otherwise.
Opipramol (Insidon),
tianeptine (Stablon, Coaxil) and
amineptine (discontinued; formerly Survector, Maneon) are chemically TCAs but are
pharmacodynamically atypical, and are therefore grouped elsewhere.
Olanzapine/fluoxetine (Symbyax) – SSRI and atypical antipsychotic combination – approved as a monotherapy for bipolar depression and treatment-resistant depression
^Tatsumi M, Groshan K, Blakely RD, Richelson E (11 December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–58.
doi:
10.1016/s0014-2999(97)01393-9.
PMID9537821.
^Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME (2009). "A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull. 42 (3): 57–90.
PMID19752841.
^
abCorp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8.
doi:
10.4088/JCP.13r08851.
PMID25295426.
^Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". Int. Rev. Neurobiol. International Review of Neurobiology. 88: 223–55.
doi:
10.1016/S0074-7742(09)88009-4.
ISBN9780123745040.
PMID19897080.
^Thase ME (2016). "Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?". Psychiatr. Clin. North Am. 39 (3): 477–86.
doi:
10.1016/j.psc.2016.04.008.
PMID27514300.
This is a complete list of clinically approved prescription
antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or
mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for
major depressive disorder unless noted otherwise.
Opipramol (Insidon),
tianeptine (Stablon, Coaxil) and
amineptine (discontinued; formerly Survector, Maneon) are chemically TCAs but are
pharmacodynamically atypical, and are therefore grouped elsewhere.
Olanzapine/fluoxetine (Symbyax) – SSRI and atypical antipsychotic combination – approved as a monotherapy for bipolar depression and treatment-resistant depression
^Tatsumi M, Groshan K, Blakely RD, Richelson E (11 December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–58.
doi:
10.1016/s0014-2999(97)01393-9.
PMID9537821.
^Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME (2009). "A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull. 42 (3): 57–90.
PMID19752841.
^
abCorp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8.
doi:
10.4088/JCP.13r08851.
PMID25295426.
^Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". Int. Rev. Neurobiol. International Review of Neurobiology. 88: 223–55.
doi:
10.1016/S0074-7742(09)88009-4.
ISBN9780123745040.
PMID19897080.
^Thase ME (2016). "Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?". Psychiatr. Clin. North Am. 39 (3): 477–86.
doi:
10.1016/j.psc.2016.04.008.
PMID27514300.